Access the full text.
Sign up today, get DeepDyve free for 14 days.
TE Ind EC Brockbank (2004)
Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancerInt J Gynecol Cancer, 14
S. Eisenkop, N. Spirtos, W. Lin (2006)
"Optimal" cytoreduction for advanced epithelial ovarian cancer: a commentary.Gynecologic oncology, 103 1
O. Zivanovic, C. Sima, A. Iasonos, W. Hoskins, P. Pingle, M. Leitao, Y. Sonoda, N. Abu-Rustum, R. Barakat, D. Chi (2010)
The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum.Gynecologic oncology, 116 3
S. Eisenkop, N. Spirtos, R. Friedman, W. Lin, A. Pisani, S. Perticucci (2003)
Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study.Gynecologic oncology, 90 2
Java JJ Tewari D (2014)
a gynecologic oncology group study. J Clin Oncol
A. Hendrickson, Kieran Hawthorne, E. Goode, K. Kalli, Krista Goergen, J. Bakkum-Gamez, W. Cliby, G. Keeney, D. Visscher, Y. Tarabishy, A. Oberg, L. Hartmann, M. Maurer (2015)
Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo ClinicGynecologic oncology, 137
W. Hoskins, B. Bundy, J. Thigpen, G. Omura (1992)
The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study.Gynecologic oncology, 47 2
K Fuh,T.K.Kiet,L Chen,R A Brooks,A E Sherman,D S Kapp,J K Chan The use of molecular markers to predict for optimal cytoreduction in ovarian cancer.
G. Aletti, S. Dowdy, B. Gostout, M. Jones, C. Stanhope, T. Wilson, K. Podratz, W. Cliby (2006)
Aggressive Surgical Effort and Improved Survival in Advanced-Stage Ovarian CancerObstetrics & Gynecology, 107
H. Steed, A. Oza, J. Murphy, S. Laframboise, G. Lockwood, D. Petrillo, J. Sturgeon, B. Rosen (2006)
A retrospective analysis of neoadjuvant platinum‐based chemotherapy versus up‐front surgery in advanced ovarian cancerInternational Journal of Gynecological Cancer, 16
D. Chi, O. Zivanovic, M. Palayekar, E. Eisenhauer, N. Abu-Rustum, Y. Sonoda, D. Levine, M. Leitao, C. Brown, R. Barakat (2009)
A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma.Gynecologic oncology, 112 1
Rudy Suidan, P. Ramirez, D. Sarasohn, J. Teitcher, S. Mironov, R. Iyer, Qin Zhou, A. Iasonos, H. Paul, M. Hosaka, C. Aghajanian, M. Leitao, G. Gardner, N. Abu-Rustum, Y. Sonoda, D. Levine, H. Hricak, D. Chi (2014)
A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer.Gynecologic oncology, 134 3
Chad Hamilton, Austin Miller, Caela Miller, T. Krivak, John Farley, Mildred Chernofsky, M. Stany, G. Rose, M. Markman, Robert Ozols, Deborah Armstrong, G. Maxwell (2011)
The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study.Gynecologic oncology, 122 3
Alison Karst, R. Drapkin (2009)
Ovarian Cancer Pathogenesis: A Model in EvolutionJournal of Oncology, 2010
C. Fotopoulou, R. Richter, E. Braicu, S. Schmidt, W. Lichtenegger, J. Sehouli (2010)
Can complete tumor resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 36 12
A. Elattar, A. Bryant, B. Winter-Roach, Mohamed Hatem, R. Naik (2011)
Optimal primary surgical treatment for advanced epithelial ovarian cancer.The Cochrane database of systematic reviews, 8
E. Chéreau, M. Ballester, F. Selle, A. Cortez, E. Daraï, R. Rouzier (2010)
Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer.American journal of obstetrics and gynecology, 202 2
Bryant A Elattar A (2011)
Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R 2011.Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev. 10;(8)
Anis Kaldawy, Y. Segev, O. Lavie, R. Auslender, V. Sopik, S. Narod (2016)
Low-grade serous ovarian cancer: A review.Gynecologic oncology, 143 2
Alvarez RD Morgan RJ Jr, version National comprehensive cancer networks. Ovarian cancer (2013)
1199–1209.
A. Heintz, F. Odicino, P. Maisonneuve, M. Quinn, J. Benedet, W. Creasman, H. Ngan, S. Pecorelli, U. Beller (2003)
Carcinoma of the OvaryInternational Journal of Gynecology & Obstetrics, 95
S. Eisenkop, R. Friedman, He-jing Wang (1998)
Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.Gynecologic oncology, 69 2
K. Fuh, T. Kiet, L. Chen, A. Sherman, D. Kapp, J. Chan (2011)
The use of molecular markers to predict for optimal cytoreduction in ovarian cancerGynecologic Oncology, 125
J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D. Parkin, D. Forman, F. Bray (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 136
Tropé CG Vergote I, European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group, NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med (2010)
363(10):943–953
E. Braicu, J. Sehouli, R. Richter, K. Pietzner, W. Lichtenegger, C. Fotopoulou (2012)
Primary versus secondary cytoreduction for epithelial ovarian cancer: a paired analysis of tumour pattern and surgical outcome.European journal of cancer, 48 5
Hawthorne KM Wahner Hendrickson AE (2015)
Wahner Hendrickson AE, Hawthorne KM, Goode EL, Kalli KR, Goergen KM, Bakkum-Gamez JN, Cliby WA, Keeney GL, Visscher DW, Tarabishy Y, Oberg AL, Hartmann LC, Maurer MJ 2015. Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic. Gynecol Oncol. 22.
D. Tewari, J. Java, R. Salani, D. Armstrong, M. Markman, T. Herzog, B. Monk, J. Chan (2015)
Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study.Obstetrical & Gynecological Survey
I. Vergote, C. Tropé, F. Amant, G. Kristensen, T. Ehlen, N. Johnson, R. Verheijen, M. Burg, Á. Lacave, P. Panici, G. Kenter, A. Casado, C. Mendiola, C. Coens, L. Verleye, G. Stuart, S. Pecorelli, N. Reed (2010)
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.The New England journal of medicine, 363 10
E. Lengyel (2010)
Ovarian cancer development and metastasis.The American journal of pathology, 177 3
R. Bristow, Rafael Tomacruz, D. Armstrong, E. Trimble, F. Montz (2002)
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 5
D. Chi, E. Eisenhauer, J. Lang, J. Huh, L. Haddad, N. Abu-Rustum, Y. Sonoda, D. Levine, M. Hensley, R. Barakat (2006)
What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)Gynecologic Oncology, 103
E. Brockbank, T. Ind, T. Ind, D. Barton, John Shepherd, John Shepherd, Martin Gore, R. A’Hern, J. Bridges (2003)
Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancerInternational Journal of Gynecologic Cancer, 14
S. Shim, S. Lee, S. Kim, Soo‐Nyung Kim, Daeyeon Kim, Jong Lee, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, J. Nam (2015)
Nomogram for predicting incomplete cytoreduction in advanced ovarian cancer patients.Gynecologic oncology, 136 1
Abstract The purpose of this study was to correlate the pattern of spread with oncological outcomes in advanced ovarian cancer patients. This is a retrospective analysis of 55 consecutive patients who had advanced epithelial ovarian cancer or primary peritoneal carcinomatosis (stages 3C and 4) with primary surgical intervention as the initial modality of treatment. Based on the spread of disease, they were further classified into class A: disease confined to the pelvis (excluded); class B: disease extending to the lower abdomen and omentum; class C: diffuse small-bowel disease with or without A, B, or D; and class D: disease in the upper abdomen. There were 17 patients (30.9%) in class B, 17 (30.9%) in class C, and 21 (38.2%) in class D. The number of patients with suboptimal cytoreduction was highest in class C (six patients). At the end of follow-up (median 38.6 months), 16 patients had no evidence of disease and 26 patients were alive with disease. The 3-year overall survival rates in classes B, C, and D were 94.1, 52.5, and 93.3%, respectively. The 3-year progression-free survival rates were 55.8, 11.8, and 41.9%, respectively. The rates were lowest for class C. The differences in the overall survival rate (p < 0.001) and progression-free survival rate (p = 0.001) were statistically significant. In advanced ovarian cancer patients, the presence of disease in the small-bowel serosa and mesentery results in poorer outcomes in terms of overall and progression-free survival. The number of patients with suboptimal cytoreduction was also highest in this group.
Indian Journal of Surgical Oncology – Springer Journals
Published: Jun 1, 2018
Keywords: surgical oncology; oncology; surgery
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.